Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone alone versus prednisone + tacrolimus for podocytopathy in chronic kidney disease
ChiCTR2200066011Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Dec 2022
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of prednisone and tacrolimus in Podocytopathies and chronic kidney disease (CKD) (2 arms), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoints: Proteinuria remission rate, Renal biopsy pathological results and 6 more. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
prednisonetacrolimus
03
Conditions
Podocytopathieschronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2200066011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066011.